Scholarlink

Objective <p>The objective of this study was to comprehensively characterize the expression profiles and prognostic significance of palmitoylation-related genes (PRGs) in bladder cancer (BLCA).</p> Methods <p>Transcriptomic, clinical, and somatic mutation data of BLCA patients were obtained from The Cancer Genome Atlas (TCGA) and the GEO dataset (GSE13507), and batch effects were corrected using the ComBat method. Consensus clustering was performed to identify PRG-related molecular subtypes. Prognostic differentially expressed genes (DEGs) were further used for gene subtyping, and a PRG-based prognostic risk model was constructed by applying the least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression. CIBERSORT assessed immune infiltration, while scRNA-seq data from Tumor Immune Single-cell Hub (TISCH) analyzed core gene expression in cell clusters. The biological function of the core gene was validated by Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR), Western blotting, wound-healing, colony-formation, and EdU assays.</p> Results <p>Two distinct PRG-related molecular subtypes and two gene subtypes were identified. The nine core genes (including MXRA8) showed robust predictive performance (AUC &gt; 0.7 for 1-, 3-, and 5-year overall survival) and was incorporated into a nomogram along with clinical parameters. MXRA8 was highly expressed in BLCA tissues at both transcript and protein levels and predominantly expressed in fibroblast and myofibroblast clusters. Functionally, silencing MXRA8 significantly suppressed BLCA cell proliferation, migration, and invasion.</p> Conclusions <p>The PRG-based risk score serves as a robust and clinically applicable tool for prognostic evaluation and predicting chemotherapy response. Furthermore, MXRA8 may serve as a potential molecular hub for developing precision medicine–oriented therapeutic strategies in BLCA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MXRA8, a key palmitoylation-related gene, promotes bladder cancer progression via remodeling tumor microenvironment and predicts poor prognosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月8日

查看全文
  • Hailong Wang,
  • Ye Xiong,
  • Tianchi He,
  • Mingyang He,
  • Jun Deng,
  • Dianbin Song,
  • Zhipeng Wang

摘要

Objective

The objective of this study was to comprehensively characterize the expression profiles and prognostic significance of palmitoylation-related genes (PRGs) in bladder cancer (BLCA).

Methods

Transcriptomic, clinical, and somatic mutation data of BLCA patients were obtained from The Cancer Genome Atlas (TCGA) and the GEO dataset (GSE13507), and batch effects were corrected using the ComBat method. Consensus clustering was performed to identify PRG-related molecular subtypes. Prognostic differentially expressed genes (DEGs) were further used for gene subtyping, and a PRG-based prognostic risk model was constructed by applying the least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression. CIBERSORT assessed immune infiltration, while scRNA-seq data from Tumor Immune Single-cell Hub (TISCH) analyzed core gene expression in cell clusters. The biological function of the core gene was validated by Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR), Western blotting, wound-healing, colony-formation, and EdU assays.

Results

Two distinct PRG-related molecular subtypes and two gene subtypes were identified. The nine core genes (including MXRA8) showed robust predictive performance (AUC > 0.7 for 1-, 3-, and 5-year overall survival) and was incorporated into a nomogram along with clinical parameters. MXRA8 was highly expressed in BLCA tissues at both transcript and protein levels and predominantly expressed in fibroblast and myofibroblast clusters. Functionally, silencing MXRA8 significantly suppressed BLCA cell proliferation, migration, and invasion.

Conclusions

The PRG-based risk score serves as a robust and clinically applicable tool for prognostic evaluation and predicting chemotherapy response. Furthermore, MXRA8 may serve as a potential molecular hub for developing precision medicine–oriented therapeutic strategies in BLCA.